HOME   |    PDF   |   


Title

Towards the design of epitope candidates for Coronavirus 2

Authors

Hasanain Abdulhameed Odhar*, Salam Waheed Ahjel, Suhad Sami Humadi

 

Affiliation

Department of pharmacy, Al-Zahrawi University College, Karbala, Iraq

 

Email

Hasanain Abdulhameed Odhar - Tel: 009647725300923; Email:
hodhar3@gmail.com; *Corresponding author

 

Article Type

Research Article

 

Date

Received April 4, 2020; Revised April 12, 2020; Accepted April 12, 2020; Published May 31, 2020

 

Abstract

The severe acute respiratory syndrome coronavirus-2, formerly known as 2019 novel coronavirus, is a pandemic public health threat. This beta coronavirus potentially infects the alveolar cells of the lung leading to pneumonia. The disease may progress into acute respiratory distress syndrome especially in elderly patients with comorbidities. Therefore, it is of interest to design and develop candidates for treatment, therapy and prevention. The spike glycoprotein of the virus known to potentially interact with angiotensin converting enzyme 2 as a cell entry receptor is a suitable candidate for further consideration as vaccine and treatment candidate. Hence, we screened the spike protein of coronavirus-2 for potential B-cell and T-cell epitopes for further deliberation. Thus, we document several peptides on the spike protein with predicted high antigenicity, low allergenicity and good stability against selected proteases. The linear B-cell epitope with sequence GFNCYFPLQSYGF is of particular interest in this context towards the design and development of short peptide vaccine candidates for combat and care against the virus.

 

Keywords

SARS-CoV-2, 2019-nCoV, COVID-19, vaccine, epitope

 

Citation

Odhar et al. Bioinformation 16(5): 375-386 (2020)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.